SNDX
Closed
Syndax Pharmaceuticals Inc
8.82
-0.55 (-5.87%)
Last Update: 01 Jul 2025 23:03:00
Yesterday: 9.365
Day's Range: 8.775 - 9.4
Send
sign up or login to leave a comment!
When Written:
19.71
Syndax Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing therapies for cancer treatment. The company was founded in 2005 and is headquartered in Waltham, Massachusetts. Syndax's lead product candidate, entinostat, is a selective histone deacetylase (HDAC) inhibitor that is being developed for the treatment of various cancers, including breast cancer and non-small cell lung cancer. The company is also developing a pipeline of other cancer therapies, including SNDX-6352, a monoclonal antibody targeting colony-stimulating factor 1 receptor (CSF1R), and SNDX-5613, a menin inhibitor for the treatment of acute leukemias. Syndax has partnerships with various pharmaceutical companies, including Merck, Pfizer, and Genentech.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








